Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising data in initial human assessments . Current https://geniusbookmarks.com/story21350664/retatrutide-emerging-research-and-possible-medical-uses